Systemic adjuvant therapies for breast cancer

2005 ◽  
pp. 440-454
Author(s):  
Jean Abraham ◽  
Cheryl Palmer ◽  
Bristi Basu ◽  
Helena Earl
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapies

Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer

2010 ◽  
Vol 36 ◽  
pp. S62-S66 ◽  
Author(s):  
V. Guarneri ◽  
E. Barbieri ◽  
M.V. Dieci ◽  
F. Piacentini ◽  
P. Conte
Keyword(s):  
Breast Cancer ◽  
Her2 Positive ◽  
Adjuvant Therapies ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer

2017 ◽  
Vol 77 (10) ◽  
pp. 1079-1087 ◽  
Author(s):  
Volker Möbus ◽  
Susanne Hell ◽  
Marcus Schmidt
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Clinical Benefit ◽  
Early Stage ◽  
Survival Rates ◽  
Disease Free Survival ◽  
New Drugs ◽  
Early Stage Breast Cancer ◽  
Risk Of Recurrence ◽  
Adjuvant Therapies

AbstractOncologic therapy is currently undergoing significant changes. A number of innovative targeted medications currently in clinical development have raised high expectations. With that in mind, discussions about terms such as “clinical benefit” and “clinical relevance” are highly topical. This also applies to further developments in the field of adjuvant systemic therapies for early-stage breast cancer. As the treatment aim is curative, assessment of the clinical benefit of adjuvant therapies must be largely based on efficacy outcomes. The focus must be on improving disease-free survival rates and lowering the risk of recurrence. Because of the current low mortality rates, statements about overall survival rates are only possible after very long observation periods. Consequently, new drugs in adjuvant therapies should be considered as offering a clinical benefit, if they reduce the risk of recurrence below current low levels of risk. The evidence for established adjuvant therapy standards in early-stage breast cancer can be used as objective criteria for comparison. This review article considers the requirements for clinical benefit of new adjuvant therapies for early breast cancer, based on examples from adjuvant endocrine therapy, adjuvant polychemotherapy and adjuvant anti-HER2 therapy.

scholarly journals Comparative efficacy of non-pharmacological adjuvant therapies for quality of life in the patients with breast cancer receiving chemo- or radio-therapy

Medicine ◽  
2018 ◽  
Vol 97 (35) ◽  
pp. e12096 ◽  
Author(s):  
Zhiyun He ◽  
Ailin Song ◽  
Zhongtao Zhang ◽  
Youcheng Zhang ◽  
Xiaokang Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Comparative Efficacy ◽  
Adjuvant Therapies ◽  
Radio Therapy

Clinical potential of new antiestrogens.

1997 ◽  
Vol 15 (2) ◽  
pp. 840-852 ◽  
Author(s):  
W J Gradishar ◽  
V C Jordan
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Bone Density ◽  
Clinical Experience ◽  
Advanced Disease ◽  
Adjuvant Therapies ◽  
Laboratory Development ◽  
Medical Indications ◽  
Clinical Potential

PURPOSE Based on the data and clinical experience derived from tamoxifen usage, the properties of an ideal antiestrogen is described that could have applications as a breast cancer preventative agent, long-term adjuvant therdpy, or as a treatment for osteoporosis. Each of the new antiestrogens currently being tested is discussed in terms of laboratory development, toxicology, pharmacology, endocrinology, and clinical evaluation. And each new compound is assessed according to the properties of an ideal antiestrogen. METHODS A review of all published reports was facilitated by the use of Medline computer searches. RESULTS Numerous compounds are being evaluated in clinical trials and can be categorized as triphenylethylenes or tamoxifen analogs, pure antiestrogens, and targeted antiestrogens. Several of these compounds may have fewer uterotropic properties and greater effects on maintaining bone density compared with tamoxifen; however, the clinical experience (ie, patient-years of treatment) with any of these compounds is minimal. CONCLUSION Although many of these compounds appear promising, further evaluation will be necessary to determine the role these compounds may serve as preventive agents, adjuvant therapies, treatments for advanced disease, or other medical indications such as osteoporosis.

Sign in / Sign up

Export Citation Format

Share Document